AD 416
Alternative Names: AD-416Latest Information Update: 15 May 2024
At a glance
- Originator Apnimed
- Class Sleep disorder therapies
- Mechanism of Action Adrenergic uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sleep apnoea syndrome
Most Recent Events
- 15 Apr 2024 Preclinical trials in Sleep apnoea syndrome in USA (unspecified route) (Apnimed pipeline, April 2024)